Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Psoriasis 4Lymphoma, Follicular 4Arthritis, Rheumatoid 3Pruritus 1Prostatic Neoplasms 1Plaque, Amyloid 1Bronchiolitis Obliterans Syndrome 1Bites and Stings 1Asthma 1Arthritis, Juvenile 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2AMG 757 2durvalumab 1dostarlimab 1cemiplimab 1atezolizumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Hydroxyurea 1Etoposide 1Etanercept 1Carboplatin 1Androgen Receptor Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bites and Stings × Etanercept × Clear all
NCT03792841 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Amgen

Phase 1 Terminated
212 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡